{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T02:28:15Z","timestamp":1789439295219,"version":"build-2803163510"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["1722665"],"award-info":[{"award-number":["1722665"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"U.S. Department of Health & Human Services | Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["NU38OT000141"],"award-info":[{"award-number":["NU38OT000141"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Arnold Ventures through a grant to Johns Hopkins; and Coalition for Global Hepatitis Elimination, a program of the Task Force for Global Health."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-74734-1","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T12:27:48Z","timestamp":1782995268000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Projected health benefits and cost offsets from the United States National Hepatitis C Elimination Initiative"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8741-4430","authenticated-orcid":false,"given":"Jagpreet","family":"Chhatwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alec","family":"Aaron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2902-1644","authenticated-orcid":false,"given":"Huaiyang","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risha","family":"Irvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey J.","family":"Alter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueran","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M.","family":"Sharfstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"74734_CR1","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1001\/jama.2023.3692","volume":"329","author":"RL Fleurence","year":"2023","unstructured":"Fleurence, R. L. & Collins, F. S. A National Hepatitis C Elimination Program in the United States: a historic opportunity. JAMA 329, 1251\u20131252 (2023).","journal-title":"JAMA"},{"key":"74734_CR2","unstructured":"U.S. Department of Health and Human Services. Fiscal Year 2025 President\u2019s Budget for HHS. https:\/\/www.hhs.gov\/sites\/default\/files\/fy-2025-budget-in-brief.pdf (2024)."},{"key":"74734_CR3","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1056\/NEJMe1403619","volume":"370","author":"TJ Liang","year":"2014","unstructured":"Liang, T. J. & Ghany, M. G. Therapy of hepatitis C-back to the future.  N. Engl. J. Med. 370, 2043\u20132047 (2014). (In eng).","journal-title":"N. Engl. J. Med."},{"key":"74734_CR4","doi-asserted-by":"crossref","unstructured":"QuickStats: percentage of adults aged \u226518 years with current hepatitis C virus infection, by health insurance coverage \u2014 National Health and Nutrition Examination Survey, United States, January 2017\u2013March 2020. MMWR Morb. Mortal Wkly. Rep. 71, 1035 (2022).","DOI":"10.15585\/mmwr.mm7132a4"},{"key":"74734_CR5","unstructured":"Hepatitis C. Surveillance 2020. Source: division of viral hepatitis, National Center for HIV, Viral Hepatitis, STD, and TB Prevention. Centers for Disease Control and Prevention. https:\/\/www.cdc.gov\/hepatitis\/statistics\/2020surveillance\/hepatitis-c.htm (2023)."},{"key":"74734_CR6","doi-asserted-by":"crossref","unstructured":"Ryerson A. B., Schillie S., Barker L. K., Kupronis B. A., Wester C. Vital signs: newly reported acute and chronic hepatitis C cases\u2015United States, 2009\u20132018. Morbidity and Mortality Weekly Report 69, 399 (2020).","DOI":"10.15585\/mmwr.mm6914a2"},{"key":"74734_CR7","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1056\/NEJMe1513245","volume":"373","author":"JW Ward","year":"2015","unstructured":"Ward, J. W. & Mermin, J. H. Simple, effective, but out of reach? Public health implications of HCV drugs. N. Engl. J. Med. 373, 2678\u20132680 (2015).","journal-title":"N. Engl. J. Med."},{"key":"74734_CR8","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1056\/NEJMp2004438","volume":"383","author":"AM Daniels","year":"2020","unstructured":"Daniels, A. M. & Studdert, D. M. Hepatitis C treatment in prisons - incarcerated people\u2019s uncertain right to direct-acting antiviral therapy. N. Engl. J. Med. 383, 611\u2013613 (2020).","journal-title":"N. Engl. J. Med."},{"key":"74734_CR9","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1093\/cid\/ciz976","volume":"71","author":"KN Ly","year":"2020","unstructured":"Ly, K. N. et al. Deaths associated with hepatitis C virus infection among residents in 50 states and the District of Columbia, 2016\u20132017. Clin. Infect. Dis. 71, 1149\u20131160 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"74734_CR10","doi-asserted-by":"publisher","first-page":"118","DOI":"10.7326\/M18-0186","volume":"169","author":"N Sood","year":"2018","unstructured":"Sood, N., Ung, D., Shankar, A. & Strom, B. L. A novel strategy for increasing access to treatment for hepatitis C virus infection for medicaid beneficiaries. Ann. Intern Med 169, 118\u2013119 (2018). (In eng).","journal-title":"Ann. Intern Med"},{"key":"74734_CR11","unstructured":"National Academies of Sciences, Engineering and Medicine. A national strategy for the elimination of hepatitis B and C: phase two report. (National Academies Press, 2017)."},{"key":"74734_CR12","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1001\/jama.2018.15782","volume":"320","author":"MR Trusheim","year":"2018","unstructured":"Trusheim, M. R., Cassidy, W. M. & Bach, P. B. Alternative state-level financing for hepatitis c treatment\u2014the \u201cnetflix model. JAMA 320, 1977\u20131978 (2018).","journal-title":"JAMA"},{"key":"74734_CR13","unstructured":"Silverman E. The \u2018Netflix\u2019 model for hepatitis C drugs is saving Australia a lot of money. https:\/\/www.statnews.com\/pharmalot\/2019\/02\/15\/australia-netflix-heptitis-drug-prices\/ (2023)."},{"key":"74734_CR14","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.cgh.2016.09.015","volume":"15","author":"J Chhatwal","year":"2017","unstructured":"Chhatwal, J., He, T., Hur, C. & Lopez-Olivo, M. A. Direct-acting antiviral agents for patients with hepatitis C virus genotype 1 infection are cost-saving. Clin. Gastroenterol. Hepatol. 15, 827\u2013837.e8 (2017).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"74734_CR15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1001\/jamainternmed.2022.5699","volume":"183","author":"E Ogawa","year":"2023","unstructured":"Ogawa, E. et al. Association of direct-acting antiviral therapy with liver and nonliver complications and long-term mortality in patients with chronic hepatitis C. JAMA Intern. Med. 183, 97\u2013105 (2023).","journal-title":"JAMA Intern. Med."},{"key":"74734_CR16","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1017\/bca.2022.9","volume":"13","author":"HS Banzhaf","year":"2022","unstructured":"Banzhaf, H. S. The value of statistical life: a meta-analysis of meta-analyses. J. Benefit-Cost. Anal. 13, 182\u2013197 (2022).","journal-title":"J. Benefit-Cost. Anal."},{"key":"74734_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1017\/bca.2018.26","volume":"10","author":"LA Robinson","year":"2019","unstructured":"Robinson, L. A., Hammitt, J. K. & O\u2019Keeffe, L. Valuing mortality risk reductions in global benefit-cost analysis. J. Benefit-Cost. Anal. 10, 15\u201350 (2019).","journal-title":"J. Benefit-Cost. Anal."},{"key":"74734_CR18","unstructured":"Updating Value per Statistical Life (VSL) estimates for inflation and changes in real income. 2021. The HHS Office of the Assistant Secretary for Planning and Evaluation. https:\/\/aspe.hhs.gov\/sites\/default\/files\/2021-07\/hhs-guidelines-appendix-d-vsl-update.pdf (2023)."},{"key":"74734_CR19","unstructured":"Cloninger R., Niakan K., Schweitzer K., Silseth S. Costs and considerations for elimination of hepatitis C virus in the United States. 6, https:\/\/www.milliman.com\/en\/insight\/costs-considerations-hep-c-elimination (2023)."},{"key":"74734_CR20","first-page":"1138","volume":"28","author":"DE Kaplan","year":"2022","unstructured":"Kaplan, D. E. et al. Cost-effectiveness of direct-acting antivirals for chronic hepatitis C virus in the United States from a payer perspective. J. Manag. Care Spec. Pharm. 28, 1138\u20131148 (2022).","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"74734_CR21","volume":"18","author":"DN Scott","year":"2022","unstructured":"Scott, D. N. et al. Assessment of the cost-effectiveness of Australia\u2019s risk-sharing agreement for direct-acting antiviral treatments for hepatitis C: a modelling study. Lancet Reg. Health West Pac. 18, 100316 (2022).","journal-title":"Lancet Reg. Health West Pac."},{"key":"74734_CR22","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S2468-1253(20)30008-X","volume":"5","author":"N Scott","year":"2020","unstructured":"Scott, N. et al. A model of the economic benefits of global hepatitis C elimination: an investment case. Lancet Gastroenterol. Hepatol. 5, 940\u2013947 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"74734_CR23","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1001\/jama.2012.144878","volume":"308","author":"AJ van der Meer","year":"2012","unstructured":"van der Meer, A. J. et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308, 2584\u20132593 (2012).","journal-title":"JAMA"},{"key":"74734_CR24","doi-asserted-by":"publisher","first-page":"293","DOI":"10.7326\/M13-1133","volume":"160","author":"MM Denniston","year":"2014","unstructured":"Denniston, M. M. et al. Chronic Hepatitis C Virus Infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann. Intern. Med. 160, 293\u2013300 (2014).","journal-title":"Ann. Intern. Med."},{"key":"74734_CR25","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jhep.2008.07.029","volume":"50","author":"K Lang","year":"2009","unstructured":"Lang, K., Danchenko, N., Gondek, K., Shah, S. & Thompson, D. The burden of illness associated with hepatocellular carcinoma in the United States. J. Hepatol. 50, 89\u201399 (2009).","journal-title":"J. Hepatol."},{"key":"74734_CR26","doi-asserted-by":"publisher","unstructured":"Hofmeister M. G., et al. Estimating prevalence of hepatitis C virus infection in the United States, 2013\u20132016. Hepatology (Baltimore, Md) https:\/\/doi.org\/10.1002\/hep.30297 (2018).","DOI":"10.1002\/hep.30297"},{"key":"74734_CR27","unstructured":"Team RC. R.: A Language and Environment for Statistical Computing: R Foundation for Statistical Computing, (2024)."},{"key":"74734_CR28","doi-asserted-by":"publisher","first-page":"e186371","DOI":"10.1001\/jamanetworkopen.2018.6371","volume":"1","author":"ES Rosenberg","year":"2018","unstructured":"Rosenberg, E. S. et al. Prevalence of hepatitis C virus infection in US states and the District of Columbia, 2013 to 2016. JAMA Netw. Open 1, e186371\u2013e186371 (2018).","journal-title":"JAMA Netw. Open"},{"key":"74734_CR29","unstructured":"Hep corrections. http:\/\/www.hepcorrections.org\/ (2023)."},{"key":"74734_CR30","doi-asserted-by":"crossref","unstructured":"Spaulding A. C., Anderson E. J., Khan M. A., Taborda-Vidarte C. A., Phillips J. A. HIV and HCV in U.S. prisons and jails: the correctional facility as a bellwether over time for the community\u2019s infections. AIDS Reviews 19, (2017).","DOI":"10.24875\/AIDSRev.M17000006"},{"key":"74734_CR31","doi-asserted-by":"publisher","unstructured":"Varan A. K., Mercer D. W., Stein M. S., Spaulding A. C. Hepatitis C seroprevalence among prison inmates since 2001: still high but declining. Public health reports. (Washington, DC: 1974). 129, 187\u2013195.https:\/\/doi.org\/10.1177\/003335491412900213 (2014).","DOI":"10.1177\/003335491412900213"},{"key":"74734_CR32","unstructured":"Viral hepatitis surveillance report 2019. Viral Hepatitis Surveillance - United States. Centers for Disease Control and Prevention, July 5, 2022. (https:\/\/www.cdc.gov\/hepatitis\/statistics\/2019surveillance\/HepC.htm). (2021)."},{"key":"74734_CR33","doi-asserted-by":"publisher","first-page":"482","DOI":"10.2105\/AJPH.2013.301601","volume":"104","author":"RM Klevens","year":"2014","unstructured":"Klevens, R. M., Liu, S., Roberts, H., Jiles, R. B. & Holmberg, S. D. Estimating acute viral hepatitis infections from nationally reported cases. Am. J. Public Health 104, 482\u2013487 (2014).","journal-title":"Am. J. Public Health"},{"key":"74734_CR34","unstructured":"Prevention CfDCa. Viral Hepatitis Surveillance\u2014United States, 2018. https:\/\/www.cdc.gov\/hepatitis\/statistics\/2018surveillance\/pdfs\/2018HepSurveillanceRpt.pdf (2020)."},{"key":"74734_CR35","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1016\/j.cgh.2017.04.046","volume":"15","author":"M Lazo","year":"2017","unstructured":"Lazo, M. et al. Confluence of epidemics of hepatitis C, diabetes, obesity, and chronic kidney disease in the United States population. Clin. Gastroenterol. Hepatol. 15, 1957\u20131964.e7 (2017).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"74734_CR36","unstructured":"Centers for Disease Control and Prevention. National Diabetes Statistics Report. https:\/\/usdss.cdc.gov\/diabetes\/report.html (2026). Accessed 27 June, 2026."},{"key":"74734_CR37","doi-asserted-by":"publisher","first-page":"e0271197","DOI":"10.1371\/journal.pone.0271197","volume":"17","author":"Y-C Chen","year":"2022","unstructured":"Chen, Y.-C., Wang, H.-W., Huang, Y.-T. & Jiang, M.-Y. Association of hepatitis C virus infection status and genotype with kidney disease risk: a population-based cross-sectional study. PLoS ONE 17, e0271197 (2022).","journal-title":"PLoS ONE"},{"key":"74734_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmedr.2020.101193","volume":"20","author":"GMA Kibria","year":"2020","unstructured":"Kibria, G. M. A. & Crispen, R. Prevalence and trends of chronic kidney disease and its risk factors among US adults: an analysis of NHANES 2003\u201318. Prev. Med. Rep. 20, 101193 (2020).","journal-title":"Prev. Med. Rep."},{"key":"74734_CR39","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1007\/s10620-015-3801-y","volume":"60","author":"F Fabrizi","year":"2015","unstructured":"Fabrizi, F., Verdesca, S., Messa, P. & Martin, P. Hepatitis C virus infection increases the risk of developing chronic kidney disease: a systematic review and meta-analysis. Dig. Dis. Sci. 60, 3801\u20133813 (2015).","journal-title":"Dig. Dis. Sci."},{"key":"74734_CR40","first-page":"e27322","volume":"14","author":"E Habas Sr.","year":"2022","unstructured":"Habas, E. Sr. Hepatitis virus C-associated nephropathy: a review and update. Cureus 14, e27322 (2022).","journal-title":"Cureus"},{"key":"74734_CR41","doi-asserted-by":"publisher","unstructured":"Mazzaro C., et al. A review on extrahepatic manifestations of chronic hepatitis C virus infection and the impact of direct-acting antiviral therapy. Viruses 13, https:\/\/doi.org\/10.3390\/v13112249 (2021).","DOI":"10.3390\/v13112249"},{"key":"74734_CR42","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1136\/gutjnl-2017-313983","volume":"67","author":"P Mahale","year":"2018","unstructured":"Mahale, P. et al. The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection. Gut 67, 553\u2013561 (2018).","journal-title":"Gut"},{"key":"74734_CR43","doi-asserted-by":"publisher","first-page":"e2514631","DOI":"10.1001\/jamanetworkopen.2025.14631","volume":"8","author":"D Jeong","year":"2025","unstructured":"Jeong, D. et al. Direct-acting antivirals and risk of hepatitis C extrahepatic manifestations. JAMA Netw. Open 8, e2514631 (2025).","journal-title":"JAMA Netw. Open"},{"key":"74734_CR44","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1093\/cid\/ciac139","volume":"75","author":"EH Teshale","year":"2022","unstructured":"Teshale, E. H., Roberts, H., Gupta, N. & Jiles, R. Characteristics of persons treated for hepatitis C using National Pharmacy Claims Data, United States, 2014\u20132020. Clin. Infect. Dis. 75, 1078\u20131080 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"74734_CR45","doi-asserted-by":"publisher","unstructured":"Zhong H., et al. Hepatitis C Elimination in rwanda: progress, feasibility, and economic evaluation. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research. 27, 918\u2013925. https:\/\/doi.org\/10.1016\/j.jval.2024.03.005 (2024).","DOI":"10.1016\/j.jval.2024.03.005"},{"key":"74734_CR46","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/S2468-1253(22)00386-7","volume":"8","author":"F Cui","year":"2023","unstructured":"Cui, F. et al. Global reporting of progress towards elimination of hepatitis B and hepatitis C. Lancet Gastroenterol. Hepatol. 8, 332\u2013342 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"74734_CR47","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1093\/cid\/ciae025","volume":"78","author":"CD Varley","year":"2024","unstructured":"Varley, C. D. et al. Success of the US Veterans Health Administration\u2019s Hepatitis C Virus Care Continuum in the Direct-acting Antiviral Era. Clin. Infect. Dis.: Off. Publ. Infect. Dis. Soc. Am. 78, 1571\u20131579 (2024). (In eng).","journal-title":"Clin. Infect. Dis.: Off. Publ. Infect. Dis. Soc. Am."},{"key":"74734_CR48","unstructured":"Duchovny, N., Kowalczyk, J., Lauchery, S. & Sajewski, S. CBO\u2019s medicare beneficiary cost-sharing. Model: A Technical Description Congressional Budget Office, (2019)."},{"key":"74734_CR49","unstructured":"Office CB. Budgetary Effects of Policies That Would Increase Hepatitis C Treatment. (https:\/\/www.cbo.gov\/publication\/60407#:~:text=By%20CBO\u2019s%20estimate%2C%20using%20that,result%20in%20averted%20spending%20of)."},{"key":"74734_CR50","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1177\/0272989X12454579","volume":"32","author":"DM Eddy","year":"2012","unstructured":"Eddy, D. M. et al. Model transparency and validation: a report of the ISPOR-SMDM modeling good research practices task force-7. Med. Decis. Mak. 32, 733\u2013743 (2012).","journal-title":"Med. Decis. Mak."},{"key":"74734_CR51","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s40273-019-00844-y","volume":"37","author":"NC B\u00fcy\u00fckkaramikli","year":"2019","unstructured":"B\u00fcy\u00fckkaramikli, N. C., Rutten-van M\u00f6lken, M. & Severens, J. L. Al M. TECH-VER: a verification checklist to reduce errors in models and improve their credibility. Pharmacoeconomics 37, 1391\u20131408 (2019).","journal-title":"Pharmacoeconomics"},{"key":"74734_CR52","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/hep.22375","volume":"48","author":"H Thein","year":"2008","unstructured":"Thein, H., Yi, Q., Dore, G. & Krahn, M. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatol. (Baltim., Md) 48, 418\u2013431 (2008).","journal-title":"Hepatol. (Baltim., Md)"},{"key":"74734_CR53","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1053\/gast.1997.v112.pm9024300","volume":"112","author":"G Fattovich","year":"1997","unstructured":"Fattovich, G. et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 112, 463\u2013472 (1997).","journal-title":"Gastroenterology"},{"key":"74734_CR54","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jhep.2009.12.028","volume":"52","author":"AC Cardoso","year":"2010","unstructured":"Cardoso, A. C. et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J. Hepatol. 52, 652\u2013657 (2010).","journal-title":"J. Hepatol."},{"key":"74734_CR55","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jhep.2004.01.005","volume":"40","author":"R Planas","year":"2004","unstructured":"Planas, R. et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J. Hepatol. 40, 823\u2013830 (2004).","journal-title":"J. Hepatol."},{"key":"74734_CR56","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1111\/j.1600-6143.2010.03037.x","volume":"10","author":"P Thuluvath","year":"2010","unstructured":"Thuluvath, P. et al. Liver transplantation in the United States, 1999\u20132008. Am. J. Transplant. 10, 1003\u20131019 (2010).","journal-title":"Am. J. Transplant."},{"key":"74734_CR57","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1053\/j.gastro.2009.09.067","volume":"138","author":"G Davis","year":"2010","unstructured":"Davis, G., Alter, M., El-Serag, H., Poynard, T. & Jennings L. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 138, 513\u2013521 (2010).","journal-title":"Gastroenterology"},{"key":"74734_CR58","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/lt.22072","volume":"16","author":"S Saab","year":"2010","unstructured":"Saab, S., Hunt, D. R., Stone, M. A., McClune, A. & Tong, M. J. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model. Liver Transpl. 16, 748\u2013759 (2010).","journal-title":"Liver Transpl."},{"key":"74734_CR59","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1111\/j.1600-6143.2010.03021.x","volume":"10","author":"R Wolfe","year":"2010","unstructured":"Wolfe, R., Roys, E. & Merion, R. Trends in Organ Donation and Transplantation in the United States, 1999\u20132008. Am. J. Transplant. 10, 961\u2013972 (2010).","journal-title":"Am. J. Transplant."},{"key":"74734_CR60","doi-asserted-by":"publisher","first-page":"397","DOI":"10.7326\/M14-1336","volume":"162","author":"J Chhatwal","year":"2015","unstructured":"Chhatwal, J., Kanwal, F., Roberts, M. S. & Dunn, M. A. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann. Intern. Med. 162, 397\u2013406 (2015).","journal-title":"Ann. Intern. Med."},{"key":"74734_CR61","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.jval.2013.07.006","volume":"16","author":"J Chhatwal","year":"2013","unstructured":"Chhatwal, J. et al. Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 Infection in the United States. Value Health 16, 973\u2013986 (2013).","journal-title":"Value Health"},{"key":"74734_CR62","first-page":"531","volume":"17","author":"C McAdam-Marx","year":"2011","unstructured":"McAdam-Marx, C. et al. All-cause and incremental per-patient per-year cost associated with chronic hepatitis C virus and associated liver complications in the United States: A managed care perspective. J. Manag Care Pharm. 17, 531\u2013546 (2011).","journal-title":"J. Manag Care Pharm."},{"key":"74734_CR63","doi-asserted-by":"crossref","unstructured":"American Diabetes A. Economic costs of diabetes in the U.S. in 2017. Diabetes Care 41, 917\u2013928 (2018).","DOI":"10.2337\/dci18-0007"},{"key":"74734_CR64","first-page":"S369","volume":"27","author":"KA Betts","year":"2017","unstructured":"Betts, K. A. et al. Medical costs for managing chronic kidney disease and related complications in patients with chronic kidney disease and type 2 diabetes. Am. J. Manag. Care 27, S369\u2013S374 (2017).","journal-title":"Am. J. Manag. Care"},{"key":"74734_CR65","unstructured":"MappingHepC. AbbVie Inc, Chicago, IL. https:\/\/mappinghepc.com\/(last accessed: 2023)."},{"key":"74734_CR66","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1002\/hep.25556","volume":"55","author":"MM Denniston","year":"2012","unstructured":"Denniston, M. M., Klevens, R. M., McQuillan, G. M. & Jiles, R. B. Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008. Hepatol. (Baltim., Md) 55, 1652\u20131661 (2012).","journal-title":"Hepatol. (Baltim., Md)"},{"key":"74734_CR67","unstructured":"Ambulatory Health Care Data. National Center for Health Statistics. Centers for Disease Control; and Prevention, Atlanta, GA, 1973-2015."},{"key":"74734_CR68","unstructured":"Hcupnet. Healthcare Cost And Utilization Project (Hcup). Agency For Healthcare Research And Quality, Rockville, MD.; 1990-2015."},{"key":"74734_CR69","unstructured":"HCUP National (Nationwide) Inpatient Sample (NIS). Healthcare Cost and Utilization Project (HCUP). Agency for Healthcare Research and Quality, Rockville, MD.; (1980\u20132015)."},{"key":"74734_CR70","unstructured":"HCUP State Emergency Department Databases (SEDD). Healthcare Cost and Utilization Project (HCUP). Agency for Healthcare Research and Quality, Rockville, MD. (2001\u20132015)."},{"key":"74734_CR71","unstructured":"HCUP Nationwide Emergency Department Sample (NEDS). Healthcare Cost and Utilization Project (HCUP). Agency for Healthcare Research and Quality, Rockville, MD. (2006\u2013015)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74734-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74734-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74734-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T12:03:23Z","timestamp":1786536203000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74734-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["74734"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-74734-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"10 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.M.S. and R.I. work part-time on a federal detail at the National Institutes of Health (NIH) and advise on the national hepatitis C initiative. J.W.W. works for the Task Force for Global Health, which receives funding for the general support of the Coalition for Global Hepatitis Elimination from Abbott, AbbVie, Cepheid, Gilead, Merck, Pharco, Roche, Siemens, VBI Vaccines, Zydus-Cadila, US governmental agencies, and philanthropic organizations. J.C. owns a partnership in Value Analytics Labs. A.A., H.Z., N.S., H.J.A., and Y.Z. report no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"8237"}}